|
Increases in CD4+ CD25+ T Cells after IL-2 Therapy; Percentages of CD25+ CD4+ T Cells |
|||
| scIL-2 dose |
Baseline |
After 3 Cycles |
Change |
|
|
|||
| 7.5 MIU |
1.0 ± 0.7 |
10.7 ± 6.7 |
9.7 ± 6.7 |
| 1.5 MIU |
0.9 ± 0.6 |
3.9 ± 2.5 |
2.9 ± 2.6 |
| Control |
1.5 ± 0.9 |
2.9 ± 1.4 |
1.5 ± 1.1 |
|
Percentages of CD25+ CD4+ T cells at baseline and after 3 cycles of scIL-2 therapy (week 24). The high dose IL-2 produced the greatest increase in CD25 percentages after scIL-2 administration. The high group had 4, the low group has 5 and none had 3. | |||
Lewis et al. Journal of Translational Medicine 2007 5:9 doi:10.1186/1479-5876-5-9 |
|||